Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Impact of Significant Eosinophilia in Patients with Myelodysplastic Syndromes: Single Institution Experience

Salwa S Saadeh, MBBS, Omar Alkharabsheh, MD, Darci Zblewski, CNP, Mrinal M. Patnaik, MDMBBS, Naseema Gangat, MBBS, Kebede H. Begna, MD, Hassan B. Alkhateeb, MD, Michelle A. Elliott, MD, Rong He, MD, Phuong Nguyen, MD, William J. Hogan, MBBCh, Mark R. Litzow, MD, Aref Al-Kali, MD

Blood (2017) 130 (Supplement 1): 5310.

https://doi.org/10.1182/blood.V130.Suppl_1.5310.5310

Published: 2017

Journal Articles

Risk of Venous Thrombotic Events (VTE) in Patients with Myelodysplastic Syndromes with 5q Deletion during Lenalidomide Therapy: Single Institution Experience

Omar Alkharabsheh, MD, Darci Zblewski, CNP, Naseema Gangat, MBBS, Kebede H. Begna, MD, Michelle A. Elliott, MD, Hassan B. Alkhateeb, MD, Mrinal M. Patnaik, MDMBBS, William J. Hogan, MBBCh, Mark R. Litzow, MD, Aref Al-Kali, MD

Blood (2017) 130 (Supplement 1): 5315.

https://doi.org/10.1182/blood.V130.Suppl_1.5315.5315

Published: 2017

Journal Articles

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase a, in Myelofibrosis

Blood (2017) 130 (Supplement 1): 1631.

https://doi.org/10.1182/blood.V130.Suppl_1.1631.1631

Published: 2017

Journal Articles

Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition with Sonidegib (LDE225) in Myeloid Malignancies

Raoul Tibes, MD PhD, Heidi Elizabeth Kosiorek, MS, Amylou Dueck, PhD, Jeanne Palmer, MD, James L. Slack, MD, Emily Ann Knight, NP, Saman Khalid Hashmi, MD, James M. Bogenberger, PhD, Darci Zblewski, CNP, William J. Hogan, MBBCh, Mark R. Litzow, MD, Ruben A Mesa, MD, James M. Foran, MD, Lisa Sproat, MD MSW, Aref Al-Kali, MD

Blood (2017) 130 (Supplement 1): 2629.

https://doi.org/10.1182/blood.V130.Suppl_1.2629.2629

Published: 2017

Journal Articles

Deficiency of Current Acute Myeloid Leukemia (AML) Response Criteria to Predict Response to Hypomethylating Agent Therapy: The Value of Long-Lasting Stable Disease

Stephanie Williams, MD, Rama Nanah, MD, Darci Zblewski, CNP, Michelle Elliott, MD, William J. Hogan, MBChB, Raoul Tibes, MD PhD, James M. Foran, MD, Mark R. Litzow, MD, Aref Al-Kali, MD

Blood (2016) 128 (22): 2799.

https://doi.org/10.1182/blood.V128.22.2799.2799

Published: 2016

Journal Articles

Outcome of Myelodysplastic Syndromes over Time in the US: A National Cancer Data Base Study from 2004-2013

Aref Al-Kali, MD, Darci Zblewski, CNP, Adam C Bartley, MS, Mrinal M Patnaik, MBBS, Naseema Gangat, MBBS, Kebede H. Begna, MD, Ayalew Tefferi, MD, Michelle Elliott, MD, William J Hogan, MBChB, Mark R. Litzow, MD, Ronald S. Go, MD

Blood (2016) 128 (22): 3604.

https://doi.org/10.1182/blood.V128.22.3604.3604

Published: 2016

Journal Articles

Outcome of Patients Younger Than 50 Years Old Diagnosed with Myelodysplastic Syndromes (MDS): Single Institution Experience

Aref Al-Kali, MD, Rong He, MD, Mrinal M Patnaik, MBBS, David S Viswanatha, MD, Patricia T. Greipp, DO, Darci Zblewski, CNP, Michelle Elliott, MD, Naseema Gangat, MBBS, Ayalew Tefferi, MD, Mark R. Litzow, MD, Phuong L. Nguyen, MD

Blood (2016) 128 (22): 5541.

https://doi.org/10.1182/blood.V128.22.5541.5541

Published: 2016

Journal Articles

Clinical Outcome of Hypomethylating Agents in Hypocellular MDS: Mayo Clinic Experience

Sonia Cerquozzi, MD, Hassan B Alkhateeb, MD, Moritz Binder, MD MPH, Darci Zblewski, CNP, Shahrukh K Hashmi, MD, Mrinal M Patnaik, MBBS, William J. Hogan, MBChB, Mark R. Litzow, MD, Aref Al-Kali, MD

Blood (2015) 126 (23): 5254.

https://doi.org/10.1182/blood.V126.23.5254.5254

Published: 2015

Journal Articles

Patients with Therapy-Related Myelodysplastic Syndromes (t-MDS) Have Shorter Median Overall Survival Than De Novo MDS: Mayo Clinic Experience

Muhanad Hreh, Darci Zblewski, CNP, Mrinal M Patnaik, MBBS, Firas Baidoun, MD, Naseema Gangat, MBBS, Dong Chen, MD PhD, Chris Hook, William J Hogan, MD, Mark R Litzow, MD, Aref Al-Kali, MD

Blood (2015) 126 (23): 5234.

https://doi.org/10.1182/blood.V126.23.5234.5234

Published: 2015

Journal Articles

ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis

Animesh Pardanani, MBBS, PhD, Terra L. Lasho, PhD, Christy Finke, BS, Darci Zblewski, CNP, Ramy Abdelrahman, M.B.,B.Ch., Emnet Wassie, MD, Naseema Gangat, MBBS, Curtis A. Hanson, MD, Rhett P. Ketterling, MD, Ayalew Tefferi, MD

Blood (2015) 126 (23): 828.

https://doi.org/10.1182/blood.V126.23.828.828

Published: 2015

Journal Articles

CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value

Animesh Pardanani, MBBS, PhD, Kaaren Reichard, MD, Darci Zblewski, CNP, Ramy Abdelrahman, M.B.,B.Ch., Emnet Wassie, MD, William G. Morice, MD PhD, Christopher L. Brooks, PhD, Curtis A. Hanson, MD, Ayalew Tefferi, MD, Dong Chen, MD PhD

Blood (2015) 126 (23): 2802.

https://doi.org/10.1182/blood.V126.23.2802.2802

Published: 2015

Journal Articles

Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

Ayalew Tefferi, MD, Betsy R. LaPlant, MS, Kebede Begna, MD, Mrinal M. Patnaik, MBBS, Terra L Lasho, PhD, Darci Zblewski, CNP, Christy Finke, BS, Lauren Schimek, Adam Pettinger, Curtis A. Hanson, MD, Naseema Gangat, MD, Animesh Pardanani, MBBS, PhD

Blood (2014) 124 (21): 634.

https://doi.org/10.1182/blood.V124.21.634.634

Published: 2014

Journal Articles

Patient Reported Symptoms and Tryptase Levels in WHO-Defined Systemic Mastocytosis (SM) Versus Mast Cell Activation Syndrome (MCAS) Versus Neither

Darci Zblewski, CNP, Ramy A. Abdelrahman, MBBCh, Dong Chen, MD PhD, Joseph H. Butterfield, MD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD

Blood (2014) 124 (21): 3204.

https://doi.org/10.1182/blood.V124.21.3204.3204

Published: 2014

Journal Articles

NPM1 +/ FLT3 - Patients with Acute Myeloid Leukemia (AML) Have Excellent Clinical Outcome Independent of Age When Treated with Cytotoxic Chemotherapy: Mayo Clinic Experience

Mehrdad Hefazi Torghabeh, MD, Mustaqeem A Siddiqui, MD, Mrinal M. Patnaik, MBBS, Alexandra Wolanskyj, MD, Darci Zblewski, CNP, Michelle Elliott, MD, William J Hogan, MD, Mark R. Litzow, MD, Aref Al-Kali, MD

Blood (2014) 124 (21): 5331.

https://doi.org/10.1182/blood.V124.21.5331.5331

Published: 2014

Journal Articles

Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms

Terra Lasho, PhD, Christy Finke, BS, Teresa K. Kimlinger, Darci Zblewski, CNP, Dong Chen, MD PhD, Mrinal M. Patnaik, MBBS, Curtis A. Hanson, MD, Christopher Brooks, PhD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD

Blood (2014) 124 (21): 5577.

https://doi.org/10.1182/blood.V124.21.5577.5577

Published: 2014

Journal Articles

Clinical Outcome of Patients Diagnosed with Myelodysplastic Syndrome-Unclassifiable (MDS-U): Single Center Experience

Firas Baidoun, MD, Dong Chen, MD PhD, Hassan Alkhateeb, MD, Darci Zblewski, CNP, Michelle Elliott, MD, William J. Hogan, MBChB, Mark Litzow, Aref Al-Kali, MD

Blood (2014) 124 (21): 3264.

https://doi.org/10.1182/blood.V124.21.3264.3264

Published: 2014

NARROW

Impact of Significant Eosinophilia in Patients with Myelodysplastic Syndromes: Single Institution Experience

Risk of Venous Thrombotic Events (VTE) in Patients with Myelodysplastic Syndromes with 5q Deletion during Lenalidomide Therapy: Single Institution Experience

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase a, in Myelofibrosis

Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition with Sonidegib (LDE225) in Myeloid Malignancies

Deficiency of Current Acute Myeloid Leukemia (AML) Response Criteria to Predict Response to Hypomethylating Agent Therapy: The Value of Long-Lasting Stable Disease

Outcome of Myelodysplastic Syndromes over Time in the US: A National Cancer Data Base Study from 2004-2013

Outcome of Patients Younger Than 50 Years Old Diagnosed with Myelodysplastic Syndromes (MDS): Single Institution Experience

Clinical Outcome of Hypomethylating Agents in Hypocellular MDS: Mayo Clinic Experience

Patients with Therapy-Related Myelodysplastic Syndromes (t-MDS) Have Shorter Median Overall Survival Than De Novo MDS: Mayo Clinic Experience

ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis

CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value

Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

Patient Reported Symptoms and Tryptase Levels in WHO-Defined Systemic Mastocytosis (SM) Versus Mast Cell Activation Syndrome (MCAS) Versus Neither

NPM1 +/ FLT3 - Patients with Acute Myeloid Leukemia (AML) Have Excellent Clinical Outcome Independent of Age When Treated with Cytotoxic Chemotherapy: Mayo Clinic Experience

Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms

Clinical Outcome of Patients Diagnosed with Myelodysplastic Syndrome-Unclassifiable (MDS-U): Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only